Highlights Marvel Biosciences Corp.

Equities

MRVL

CA57384M1077

Market Closed - Toronto S.E. Other stock markets 02:48:52 2024-05-03 pm EDT			5-day change	1st Jan Change
0.145 ^CAD	-6.45%		0.00%	+81.25%

Mar. 26	Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
Mar. 25	Marvel Biosciences Announces Positive Interim Results For MB-204	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 26	CI
Marvel Biosciences Announces Positive Interim Results For MB-204	Mar. 25	MT
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Positive Interim Results on Tau Phosphorylation with MB-204	Mar. 25	CI
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB204	Mar. 12	CI
Marvel Biosciences Corp. and Marvel Biotechnology Inc. Announces Testing MB-204 on Autism by French University	Feb. 20	CI
Marvel Biosciences Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 18	CI
Marvel Biosciences Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	Nov. 28	CI
Marvel Announces Successful Completion of Toxicology Study in Preparation for Phase 1 Human Trials	23-08-22	CI
Marvel Biosciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-23	CI
Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-29	CI
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate 4-Week Good Laboratory Practice FDA Investigational New Drug Enabling Dose-Ranging Rat Studies for its Lead Drug Candidate MB-204	23-03-09	CI
Marvel Biosciences Completes A Critical Manufacturing Milestone Required to Enter Phase 1 Human Trials Targeting Alzheimer's Disease and Depression	23-01-06	CI
Marvel Biosciences Corp. Successfully Completes Its Short Term Dose Ranging Study in Rats and Dogs for MB-204	23-01-03	CI
Marvel Biosciences Corp. Reports Earnings Results for the First Quarter Ended October 31, 2022	22-12-19	CI
Marvel Biosciences Initiates Final FDA-Required Experiment Prior to Human Trials for Lead Drug Candidate MB-204	22-12-12	MT
Marvel Biosciences Corp. Initiates Its Final Fda-Required Experiment Prior to Initiating Human Trials for Its Lead Drug Candidate Mb-204	22-12-12	CI
Marvel Biosciences Corp. and its Wholly Owned Subsidiary, Marvel Biotechnology Inc. Initiate its 7-Day Dose-Ranging, Toxicology Study, Using Rats, for its Lead Molecule MB-204	22-12-07	CI
Marvel Biosciences Corp. Reports Earnings Results for the Full Year Ended July 31, 2022	22-11-23	CI
Marvel Biosciences Corp. Lead Drug Candidate Mb-204 Demonstrates A 400% Increase in the Survival Rate of Animals Treated with A High Dose of the Cancer Treatment Cis-Platinum	22-11-22	CI
Marvel Biosciences Lead Drug Candidate Mb-204 Demonstrated Superior Anti-Anxiety Activity over FDA-Approved Istradefylline in Head-To-Head Pre-Clinical Studies	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Marvel Biosciences Corp.

Equities

MRVL

CA57384M1077

Highlights

Filters